Keywords: Dainippon Sumitomo, Latuda, Bipolar depression, Ph III

Dainippon Sumitomo's Latuda meets key endpoints in two Ph III trials in bipolar I depression

Article | 09 May 2012

Print This

Japanese drugmaker Dainippon Sumitomo Pharma (4506: JP) Co., Ltd. (DSP) announced has results from two Phase III clinical trials designed to ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in